Tianjin, 18 March 2025 - CanSino Biologics Inc.(CanSinoBIO or the Company) had the honor of welcoming Professor Adrian V. S. Hill FRS, the Director and Founder of the Jenner Institute, one of the largest vaccine institutes in academia, and Mittal Professor of Vaccinology at Oxford University.

Professor Hill was warmly greeted by CanSinoBIO’s leadership, including Dr Xuefeng Yu, the Chief Executive Officer, Dr Tao Zhu, Chief Science Officer, Ms Jing Wang, Chief Commercial Officer. He toured the Company’s R&D center, where he commended CanSinoBIO for its advancements in adenovirus-based viral vector vaccine technology. In particular, he showed interest in the Company’s global innovative inhaled vaccine and mRNA initiatives, recognizing the potential to significantly impact public health.

In the following panel discussion, Professor Hill shared notable achievements from Oxford team in vaccine research and development, especially highlighting their groundbreaking malaria vaccine, which has shown promising efficacy results against malaria in clinical trials and received WHO recommendation for use paving the way for global roll-out .

Additionally, he stated that technological innovation and international collaboration in the vaccine industry are crucial for achieving global health equity, a shared priority for all involved. Professor Hill also explored potential partnerships with innovative companies, such as CanSinoBIO, to jointly address global health challenges.

CanSinoBIO is dedicated to fostering innovation and collaboration, actively developing solutions for public health challenges worldwide while striving to promote a more equitable and secure future for all.